You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

240 Results
Document
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Document
Jun 2020
Document
Jul 2020
 
Document
Sep 2020
Guidelines and Advice
Status: Current
Apr 2021
Statistical Reports
Document
Jan 2021
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ripretinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023

Pages